Answers are grounded in this paper and cite their sources.
Nervous necrosis virus (NNV) continues to be a problematic pathogen that causes catastrophic losses in the global aquaculture industry. While DNA vaccines hold promise, their efficacy is often limited by poor delivery and rapid degradation in vivo. This study developed a novel DNA nanovaccine by encapsulating a plasmid (pCP) encoding the NNV capsid protein gene into poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) (PBVHx) nanoparticles (PBVHx@pCP) using a double emulsion-solvent evaporation method. The resulting nanoparticles were spherical with an average size of 472.5 nm, a zeta potential of −16.22 mV, exhibited a sustained plasmid release profile reaching a plateau of over 92% release by Day 25. Comprehensive biosafety assessments showed minimal cytotoxicity (cell viability >90% at 40 μg/mL) and no adverse effects on fish histology or behavior in grouper ( Epinephelus coioides ). Vaccination with PBVHx@pCP via intraperitoneal injection induced a robust immune response, characterized by significant upregulation of key immune markers (CD4, CD8, MHC-I, MHC-II, TNF-α, and IL-1β) and sustained high titres of antigen-specific IgM which demonstrated potent virus-neutralizing capacity at a 128-fold serum dilution. Crucially, challenge experiments with a virulent NNV demonstrated high protective efficacy, with relative percent survival of ca.94% at 28-day post vaccination (dpv) challenge test and ca.50% at 56 dpv challenge test. This significantly outperformed the naked pCP and empty PBVHx control groups. Correspondingly, viral loads in the brains and eyes of challenged fish were significantly reduced in the PBVHx@pCP group. Our findings unequivocally demonstrate that PBVHx nanoparticles serve as a highly efficient and safe delivery platform for DNA vaccines, significantly enhancing both the magnitude and longevity of protective immunity against NNV in groupers, thereby offering a promising strategy for disease control in sustainable aquaculture.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: